ReviewObesity surgery2026
Metabolic Bariatric Surgery for Cancer Prevention and Risk Reduction in Patients with Obesity: A GRADE-Based International Federation for the Surgery and Other Therapies for Obesity (IFSO) Position Statement.
Review in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major increasing driver of cancer burden worldwide, and intentional weight loss has emerged as a potential strategy for cancer risk reduction. Metabolic bariatric surgery (MBS) achieves sustained weight loss, but its role in cancer prevention remains uncertain. This GRADE-based International Federation for the Surgery and Other Therapies for Obesity (IFSO) position statement aimed to synthesize contemporary evidence on MBS and cancer outcomes and translate it into clinically actionable recommendations.
methodsA systematic review according to PRISMA guidelines was performed searching MEDLINE and EMBASE up to 8th March 2026. Two questions were formulated addressing MBS versus non-surgical weight-loss interventions and comparative effectiveness of MBS procedures for reducing cancer incidence. Evidence was appraised using GRADE principles.
resultsThere were no RCTs enrolling adults with obesity reporting cancer incidence after MBS. The search identified 191 records, of which 26 were included in the qualitative synthesis and a maximum of seven contributed to any single quantitative pooled estimate. Across retrospective matched cohorts, MBS was generally associated with lower incidence of several obesity-related malignancies, with point estimates favoring MBS for most cancer sites. Pooled random-effects estimates included breast cancer (IRR 0.85, 95% CI 0.80-0.91), endometrial cancer (IRR 0.38, 95% CI 0.23-0.61) and colorectal cancer (IRR 0.72, 95% CI 0.59-0.88); certainty of evidence was low to very low for all outcomes. Reported reductions were most consistent for hormone-sensitive cancers but also observed across multiple gastrointestinal and other sites with variable heterogeneity. Sensitivity analyses incorporating modern obesity management medications (OMMs) also suggested cancer incidence reductions across several sites, supporting sustained weight loss as a mediator of cancer risk reduction.
conclusionsCurrent evidence suggests that MBS is associated with reduced incidence of several obesity related cancers. However, the certainty of the evidence is limited by residual selection bias, and heterogeneity.
Indexed as
Identifiers
42834256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.